See more : Favelle Favco Berhad (7229.KL) Income Statement Analysis – Financial Results
Complete financial analysis of Roquefort Therapeutics plc (ROQ.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Roquefort Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Park-Ohio Holdings Corp. (PKOH) Income Statement Analysis – Financial Results
- FlexQube AB (publ) (FLEXQ.ST) Income Statement Analysis – Financial Results
- Revolution Bars Group plc (RBG.L) Income Statement Analysis – Financial Results
- ClimateRock (CLRCW) Income Statement Analysis – Financial Results
- Sabina Gold & Silver Corp. (0R11.L) Income Statement Analysis – Financial Results
Roquefort Therapeutics plc (ROQ.L)
About Roquefort Therapeutics plc
Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 200.00K | 0.00 | 719.00 |
| Cost of Revenue | 0.00 | 0.00 | 10.07K |
| Gross Profit | 200.00K | 0.00 | -9.35K |
| Gross Profit Ratio | 100.00% | 0.00% | -1,300.42% |
| Research & Development | 620.16K | 319.32K | 698.00 |
| General & Administrative | 1.51M | 941.00K | 375.54K |
| Selling & Marketing | 0.00 | 0.00 | 125.18K |
| SG&A | 1.51M | 941.00K | 500.72K |
| Other Expenses | 0.00 | 373.99K | 0.00 |
| Operating Expenses | 2.13M | 1.63M | 501.42K |
| Cost & Expenses | 2.13M | 1.63M | 511.48K |
| Interest Income | 1.47K | 0.00 | 0.00 |
| Interest Expense | 58.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.89K | 1.63M | 382.98K |
| EBITDA | -1.93M | 0.00 | -352.40K |
| EBITDA Ratio | -964.17% | 0.00% | -71,038.80% |
| Operating Income | -1.93M | -1.63M | -510.77K |
| Operating Income Ratio | -966.82% | 0.00% | -71,038.80% |
| Total Other Income/Expenses | 1.41K | 0.00 | -224.61K |
| Income Before Tax | -1.93M | -1.63M | -735.38K |
| Income Before Tax Ratio | -966.12% | 0.00% | -102,278.16% |
| Income Tax Expense | -187.69K | -18.89K | -200.92K |
| Net Income | -1.74M | -1.62M | -917.43K |
| Net Income Ratio | -872.27% | 0.00% | -127,598.47% |
| EPS | -0.01 | -0.02 | -0.04 |
| EPS Diluted | -0.01 | -0.02 | -0.04 |
| Weighted Avg Shares Out | 129.15M | 103.48M | 24.70M |
| Weighted Avg Shares Out (Dil) | 129.15M | 103.48M | 24.70M |
Source: https://incomestatements.info
Category: Stock Reports